These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 29420960

  • 1. Long-Term Sirolimus for Primary Immunosuppression in Heart Transplant Recipients.
    Asleh R, Briasoulis A, Kremers WK, Adigun R, Boilson BA, Pereira NL, Edwards BS, Clavell AL, Schirger JA, Rodeheffer RJ, Frantz RP, Joyce LD, Maltais S, Stulak JM, Daly RC, Tilford J, Choi WG, Lerman A, Kushwaha SS.
    J Am Coll Cardiol; 2018 Feb 13; 71(6):636-650. PubMed ID: 29420960
    [Abstract] [Full Text] [Related]

  • 2. Hypercholesterolemia after conversion to sirolimus as primary immunosuppression and cardiac allograft vasculopathy in heart transplant recipients.
    Asleh R, Briasoulis A, Pereira NL, Edwards BS, Frantz RP, Daly RC, Lerman A, Kushwaha SS.
    J Heart Lung Transplant; 2018 Nov 13; 37(11):1372-1380. PubMed ID: 30174165
    [Abstract] [Full Text] [Related]

  • 3. Effect of early conversion from CNI to sirolimus on outcomes in kidney transplant recipients with allograft dysfunction.
    Paoletti E, Ratto E, Bellino D, Marsano L, Cassottana P, Cannella G.
    J Nephrol; 2012 Nov 13; 25(5):709-18. PubMed ID: 22038336
    [Abstract] [Full Text] [Related]

  • 4. Incidence of Malignancies in Patients Treated With Sirolimus Following Heart Transplantation.
    Asleh R, Clavell AL, Pereira NL, Smith B, Briasoulis A, Alnsasra H, Kremers WK, Habermann TM, Otley CC, Li X, Edwards BS, Stulak JM, Daly RC, Kushwaha SS.
    J Am Coll Cardiol; 2019 Jun 04; 73(21):2676-2688. PubMed ID: 31146812
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Safety and immunologic benefits of conversion to sirolimus in kidney transplant recipients with long-term exposure to calcineurin inhibitors.
    Yu JH, Kim KW, Kim BM, Chung BH, Cho ML, Choi BS, Park CW, Kim YS, Yang CW.
    Korean J Intern Med; 2016 May 04; 31(3):552-9. PubMed ID: 26968190
    [Abstract] [Full Text] [Related]

  • 7. Timing of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor initiation and allograft vasculopathy progression and outcomes in heart transplant recipients.
    Asleh R, Briasoulis A, Pereira NL, Boilson BA, Edwards BS, Adigun R, Maltais S, Daly RC, Lerman A, Kushwaha SS.
    ESC Heart Fail; 2018 Dec 04; 5(6):1118-1129. PubMed ID: 30019530
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group.
    Transplantation; 2009 Jan 27; 87(2):233-42. PubMed ID: 19155978
    [Abstract] [Full Text] [Related]

  • 13. Conversion from calcineurin inhibitors to sirolimus of recipients with chronic kidney graft disease grade III for a period 2003-2011.
    Ignjatović L, Hrvacević R, Jovanović D, Kovacević Z, Vavić N, Rabrenović V, Tomić A, Aleksić P, Drasković-Pavlović B, Dujić A, Karan Z, Maksić D.
    Vojnosanit Pregl; 2013 Sep 27; 70(9):848-53. PubMed ID: 24266313
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. High incidence of rejection episodes and poor tolerance of sirolimus in a protocol with early steroid withdrawal and calcineurin inhibitor-free maintenance therapy in renal transplantation: experiences of a randomized prospective single-center study.
    Burkhalter F, Oettl T, Descoeudres B, Bachmann A, Guerke L, Mihatsch MJ, Dickenmann M, Steiger J.
    Transplant Proc; 2012 Dec 27; 44(10):2961-5. PubMed ID: 23195006
    [Abstract] [Full Text] [Related]

  • 17. Uric acid is an independent predictor of cardiac allograft vasculopathy after heart transplantation.
    Asleh R, Prasad M, Briasoulis A, Nardi V, Adigun R, Edwards BS, Pereira NL, Daly RC, Lerman A, Kushwaha SS.
    J Heart Lung Transplant; 2018 Sep 27; 37(9):1083-1092. PubMed ID: 29802086
    [Abstract] [Full Text] [Related]

  • 18. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
    Tsai MK, Wu FL, Lai IR, Lee CY, Hu RH, Lee PH.
    Int J Artif Organs; 2009 Jun 27; 32(6):371-80. PubMed ID: 19670189
    [Abstract] [Full Text] [Related]

  • 19. Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Long-term Follow-up From the Randomized SCHEDULE Study.
    Gustafsson F, Andreassen AK, Andersson B, Eiskjær H, Rådegran G, Gude E, Jansson K, Solbu D, Karason K, Arora S, Dellgren G, Gullestad L, SCHEDULE (Scandinavian heart transplant everolimus de novo study with early calcineurin inhibitors avoidance) Investigators*.
    Transplantation; 2020 Jan 27; 104(1):154-164. PubMed ID: 30893292
    [Abstract] [Full Text] [Related]

  • 20. De novo sirolimus with low-dose tacrolimus versus full-dose tacrolimus with mycophenolate mofetil after heart transplantation--8-year results.
    Guethoff S, Stroeh K, Grinninger C, Koenig MA, Kleinert EC, Rieger A, Mayr T, von Ziegler F, Reichart B, Hagl C, Schramm R, Kaczmarek I, Meiser BM.
    J Heart Lung Transplant; 2015 May 27; 34(5):634-42. PubMed ID: 25701373
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.